Comparative Pharmacology
Head-to-head clinical analysis: CIPRO XR versus CIPROFLOXACIN IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO XR versus CIPROFLOXACIN IN DEXTROSE 5.
CIPRO XR vs CIPROFLOXACIN IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
500 mg to 1000 mg orally once daily for 7 to 14 days; extended-release tablet must be swallowed whole and administered with food.
400 mg IV every 8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, allowing twice-daily dosing; due to extended-release formulation, ciprofloxacin is released over 24 hours.
Terminal elimination half-life 3.5-5 hours in healthy adults, prolonged to 6-10 hours in elderly or mild renal impairment, and up to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 40-50% of the dose; hepatic metabolism (glucuronidation, sulfation) produces active metabolites, and biliary/fecal elimination (via feces) accounts for 20-35% of the dose.
Renal excretion accounts for approximately 50-70% of an administered dose as unchanged drug; biliary/fecal excretion accounts for about 20-35% (including active drug and metabolites).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic